Ociperlimab

Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM) . Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer[1][2].

Product Specifications

CAS Number

[2342597-93-5]

Product Name Alternative

BGB-A1217

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ociperlimab.html

Purity

98.14

Solubility

10 mM in DMSO

Smiles

[Ociperlimab]

Molecular Weight

(145.12 kDa)

References & Citations

[1]Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319.|[2]Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26.